Jay R. Luly insider trades: Enanta Pharmaceuticals (ENTA) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jay reports to the SEC
Open-market buys and sales
18 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 5, 2025 | ENTA | ↓ Sell | 4,743 | $14.23 | $67K | Direct | Dec 5, 2025 (0d) |
| Feb 12, 2025 | ENTA | ↑ Buy | 45,000 | $5.69 | $256K | Direct | Feb 12, 2025 (0d) |
| Dec 6, 2024 | ENTA | ↓ Sell | 5,142 | $8.06 | $41K | Direct | Dec 10, 2024 (4d) |
| Dec 5, 2023 | ENTA | ↓ Sell | 7,230 | $9.63 | $70K | Direct | Dec 6, 2023 (1d) |
| Mar 13, 2023 | ENTA | ↓ Sell | 27,912 | $45.16 | $1.3M | Direct | Mar 14, 2023 (1d) |
| Dec 16, 2022 | ENTA | ↓ Sell | 30,000 | $44.72 | $1.3M | Direct | Dec 16, 2022 (0d) |
| Sep 15, 2021 | ENTA | ↓ Sell | 4,516 | $59.06 | $267K | Direct | Sep 17, 2021 (2d) |
| Jul 6, 2018 | ENTA | ↓ Sell | 35,000 | $125.24 | $4.4M | Direct | Jul 9, 2018 (3d) |
| May 17, 2018 | ENTA | ↓ Sell | 25,000 | $105.83 | $2.6M | Direct | May 18, 2018 (1d) |
| Mar 9, 2015 | ENTA | ↓ Sell | 15,000 | $33.37 | $501K | Direct | Mar 10, 2015 (1d) |
| Feb 20, 2015 | ENTA | ↓ Sell | 15,000 | $35.35 | $530K | Direct | Feb 20, 2015 (0d) |
| Jan 5, 2015 | ENTA | ↓ Sell | 15,000 | $50.43 | $756K | Direct | Jan 6, 2015 (1d) |
| Dec 1, 2014 | ENTA | ↓ Sell | 15,000 | $45.39 | $681K | Direct | Dec 2, 2014 (1d) |
| Nov 3, 2014 | ENTA | ↓ Sell | 15,000 | $42.52 | $638K | Direct | Nov 4, 2014 (1d) |
| Apr 1, 2014 | ENTA | ↓ Sell | 15,000 | $39.17 | $588K | Direct | Apr 2, 2014 (1d) |
| Mar 10, 2014 | ENTA | ↓ Sell | 10,000 | $38.49 | $385K | Direct | Mar 12, 2014 (2d) |
| Feb 14, 2014 | ENTA | ↓ Sell | 5,800 | $38.10 | $221K | Direct | Feb 14, 2014 (0d) |
| Jan 2, 2014 | ENTA | ↓ Sell | 5,800 | $28.05 | $163K | Direct | Jan 3, 2014 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ENTA insiders
Open-market trades in the last 12 months
About Jay R. Luly's insider trades
Jay R. Luly is President and CEO at Enanta Pharmaceuticals (ENTA). Since Jan 2, 2014, Jay has reported 1 open-market purchase worth $256K and 17 sales worth $14.5M on SEC Form 4. In the last 12 months: 1 sale ($67K).
Their filings also include grants and awards (27 filings), shares withheld for taxes (15 filings), option exercises (14 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ENTA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.